San Diego, CA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Longer-acting oligonucleotide medicines are attractive to drug developers because they can reduce dosing burden, improve treatment convenience, and potentially support better adherence in chronic diseases. The clinical impact is visible. Vutrisiran is administered once every three months, while inclisiran uses a twice-yearly maintenance schedule after initial dosing. Investigational cardiovascular siRNAs are pushing duration further: in a Phase 2 study, a single 400-mg dose of lepodisiran produced substantial Lp(a) lowering that remained evident at 18 months.